A Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Inhalers in Adults With Mild Asthma

Inclusion Criteria

• •Participants are eligible to be included in the study if all the following criteria apply:
• •Male or female; females may be of childbearing potential, of nonchildbearing potential, or postmenopausal.
• •Participant must be 18 to 45 years of age inclusive, at the time of screening.
• •Confirmed diagnosis of asthma: documented, established diagnosis of asthma for at least 6 months.
• •Receiving 1 of the following asthma treatments, at a stable dose, for at least 12 weeks prior to the screening visit and is anticipated to remain stable for the duration of the study:
• •* As needed short-acting beta-agonists (SABA) only
• •* As needed SABA plus low-dose Inhaled corticosteroids (ICS) (defined as 100-250 µg/day fluticasone propionate or equivalent taken whenever SABA is taken).
• •* Daily maintenance low-dose ICS, plus as needed SABA or ICS-SABA single inhaler combination therapy
• •* Low dose combination single inhaler ICS-formoterol or single inhaler ICS-SABA as needed for symptom relief (and if needed, before exercise)
• •* Leukotriene receptor antagonist (LTRAs) in combination with any of the above therapies
• •Asthma Control Questionnaire (ACQ)-6 score \<1.5 at screening and Day -1.
• •No severe asthma exacerbations within 6 months prior to screening and ≤1 severe exacerbation during the 12 months prior to screening.
• •Lung function: subjects with a pre-bronchodilator FEV1 ≥60% predicted at Screening and Day-1.
• •A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:
• •* Is a Woman of non-childbearing potential (WONCBP) OR
• •* Is a Woman of childbearing potential (WOCBP) and using a contraceptive method that is highly effective, with a failure rate of \<1%.
• •Female participants must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 28 days before the first dose of study intervention.
• •For male participants, no contraceptive measures are required.
• •Non-smokers, or previous smokers who have not used any tobacco containing-products or vaping products within 12 months prior to study start, and with a total pack year history of ≤10 pack years.
• •The use of marijuana, even with a valid prescription, is prohibited within 12 months prior to study start.
• •Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and protocol.